Cubist Pharmaceuticals (CBST) is a highly profitable, commercial stage biopharmaceutical company based in Lexington, Massachusetts. It began producing positive cash flows in 2007 and hasn't looked back, largely on the strength of daptomycin (Cubicin), an antibiotic it purchased from Eli Lilly (NYSE:LLY) in 1997. In 2012, daptomycin comprised 93% of Cubist's total revenue. With only a few years of daptomycin exclusivity remaining, the company is facing armageddon. Here's a look at how much Cubist stands to lose, when they might lose it, and what they're doing to prepare for the impending loss of Cubicin exclusivity.
Entereg, the first responder
The company's efforts to diversify revenue sources are tipping the scales in the right direction, largely on the back...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|